Incorporating belief in miracles into cancer care, other top stories in hematology/oncology
Click Here to Manage Email Alerts
Insight into how clinicians can integrate belief in miracles into their discussions with terminally ill patients with advanced cancer was the top story in hematology/oncology last week.
Another top story details a link between intrauterine device use and ovarian cancer.
Read the top stories in hematology/oncology below.
‘Betting on a miracle’ a barrier to prognostic understanding among patients with advanced cancer
The co-director of the Center for Research on End-of-Life Care at Weill Cornell Medicine spoke with Healio about the power of religious belief, its benefits and drawbacks, and how clinicians can incorporate belief in miracles into their conversations with terminally ill patients. Read more.
Use of intrauterine devices may decrease risk for ovarian cancer
A co-author of a meta-analysis that showed intrauterine device use may decrease the risk for incident ovarian cancer spoke with Healio about the possible mechanisms of this association and its implications for the future of ovarian cancer prevention. Read more.
Sociodemographic factors may influence survival among young adults with colorectal cancer
Young adults with colorectal cancer who resided in areas with the lowest incomes and high school graduation rates had a 24% increased risk for death compared with their counterparts in areas with the highest incomes and graduation rates, according to study results presented at Gastrointestinal Cancers Symposium. Read more.
Allogeneic hematopoietic stem cell transplant survival outcomes show ‘striking improvement’
Patients who received allogeneic hematopoietic stem cell transplants between 2013 and 2017 demonstrated substantial improvement in survival outcomes and fewer complications than those who underwent transplantation a decade earlier, according to results of a retrospective study published in Annals of Internal Medicine. Read more.
FDA approves Tazverik for advanced epithelioid sarcoma
The FDA granted accelerated approval to tazemetostat (Tazverik, Epizyme) for patients aged 16 years or older with metastatic or locally advanced epithelioid sarcoma ineligible for complete resection. Read more.